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Hypertension is one of the major risk factors for ischemic heart disease and appropriate
control of blood pressure is the cornerstone of both primary and secondary ischemic heart
disease prevention. Effective blood pressure (BP) control is recommended in primary
prevention, i.e., maintaining blood pressure o140/90 mmHg, while in secondary preven-
tion values o130/85 mmHg used to be recommended. Treatment of hypertension in
patients with ischemic heart disease is based on ACE inhibitors and/or AII antagonists
(trials HOPE, EUROPA, and PEACE) in combination with beta blockers or with verapamil if
beta blockers are not tolerated.
According to epidemiologic data, cardiovascular mortality increases with blood pres-
sure, starting as low as from the 110/70 mmHg level. Czech, European, and American
guidelines from the early 21st century recommend that blood pressure in patients with
ischemic heart disease (IHD) be maintained below 130/80 mmHg. Data from the INVEST a
ACCORD trials led, however, to reappraisal of these strict recommendations and the blood
pressure values currently recommended in secondary prevention correspond to high-
normal blood pressure, i.e., 130–139 mmHg/80–89 mmHg.
INVEST is the largest clinical trial that focused on hypertonic patients with IHD. Its
results showed that verapamil is an appropriate alternative to beta blockers and that while
lowering of blood pressure below 140/90 mmHg is necessary, its further decrease below
130/80 mmHg is not associated with any additional benefit.
Trials with beta blockers demonstrated that lowering of heart rate (HR) improves the
patients’ prognosis. This hypothesis was definitely verified by trials BEAUTIFUL a SHIFT.
The recommended heart rate for patients in secondary prevention is 50–70 bpm.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.Contents1. Hypertension and ischemic heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
2. Blood pressure control in chronic IHD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
3. Hypertension, diabetes mellitus and ischemic heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
4. Trials in diabetics with ischemic heart disease and hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
5. Ischemic heart disease and heart rate (HR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 3 3 – e 4 3 8e4346. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4371. Hypertension and ischemic heart disease
When treating patients with high blood pressure, we always
have to look for target organ damage (left ventricular hyper-
trophy, microalbuminuria, retinal angiosclerosis/retinopathy)
and for ensuing complications (ventricular dysfunction and
manifestation of ischemic disease). Cardiovascular mortality
is still high despite continuous decrease of total and cardiovas-
cular mortality in most developed countries. Timely prevention
and treatment of hypertension and ischemic heart disease can
thus result in further improvement of the current situation.
In general, hypertension doubles the risk of cardiovascular
disease and accelerates significantly the development of ather-
osclerosis [1]. Blood pressure plays a crucial role in the athero-
sclerotic process. Atherosclerosis manifests only rarely in parts
of circulation with low blood pressure, e.g., in pulmonary
arteries or veins. The risk of cardiovascular complications
increases continually along with the blood pressure, starting
as low as from the 110/70 mmHg level. Systolic blood pressure
is more predictive of mortality, especially in the elderly who
most often suffer from isolated systolic hypertension. The
situation when hypertension is not accompanied by other risk
factors for atherosclerosis is rare. On the contrary, combination
of hypertension with dyslipidemia, impaired glucose tolerance
or diabetes, abdominal obesity, hyperinsulinemia, and hyper-
uricemia is very common, lately being referred to as so-called
metabolic syndrome.
Basic workup in a hypertonic patient should include the
assessment for possible ischemic heart disease using ECG or
echocardiography (coronarography when pain or dyspnea are
present), all components of metabolic syndrome, and possi-
ble nefropathy—excluding microalbuminuria using the dip-
stick method. Detection of albumin in urine is associated
with 2–4fold increase in risk of heart damage so it should lead
not only to intensification of therapy but also to possible
further diagnostic workup. Diabetes mellitus has been linked
to similar 2–4fold risk increase.
Treatment of hypertension in patients with ischemic heart
disease is based on angiotensin-converting enzyme inhibitors
(ACE-I), which is consistent with the results of trials HOPE,
EUROPA, and PEACE [2–4] completed at the end of 20th or
beginning of the 21st century. When ACE-I are not tolerated, it
is possible to use the blockers of receptor 1 for angiotensin II
(ARB). These can be combined with beta blockers, preferably
selective, without ISA activity. Verapamil can be used in cases
of beta blocker intolerance. Patients suffering from angina can
use dihydropyridine-type calcium channel blockers; diuretics
are indicated in cases of heart failure.2. Blood pressure control in chronic IHD
The treatment of hypertension and ischemic heart disease is
being discussed continuously, especially in the context of
association between high but also low values of diastolicblood pressure and the number of IHD deaths (so-called J-
curve). HOT (Hypertension Optimal Treatment) was the first
large trial whose authors attempted to solve this question in
the 90ties [5]. It was a randomized study of hypertension with
19,193 participants from 26 countries aged 50–80 (mean: 61.5)
years, whose diastolic blood pressure was 100–115 mmHg
(mean: 105 mmHg). The patients were randomized to three
groups with different target values of diastolic blood pressure
(below 90, below 85 or below 80 mmHg). The differences
among groups concerning the rates of predefined events
and deaths according to target blood pressure values were
minimal and only the trend towards decrease of myocardial
infarction rate in the group with lower target blood pressure
reached statistical significance (28% decrease in the rate of
events with the ‘‘below 80 mmHg’’ vs ‘‘below 90 mmHg’’
target). The rate of major cardiovascular events was the
lowest with blood pressure 138.5/82.6 mmHg.
The 2007 European guidelines for evaluating and treating
hypertension state that patients with ischemic heart disease
should have their blood pressure lowered below 130/
80 mmHg [6]. Since these guidelines were re-evaluated in
2009, it is prudent to take into account the following [7,8]: Treatment target: Systolic blood pressureo140 mmHg and
diastolic blood pressure o90 mmHg are appropriate for
every patient, independently of his/her age. When con-
sidering the clinical trials it is clear, however, that no
single large clinical trial evaluated the benefit of systolic
BP lowering below 140 mmHg in the elderly. The recom-
mendations are thus based on general agreement about
the benefit but they are not a product of evidence-based
medicine (EBM). Completed large clinical trials (HOT, VALUE, INVEST,
ONTARGET) [5,9–11] demonstrate the benefit of treatment
leading to blood pressure decrease below 140/90 mmHg.
On the other hand, lowering of systolic blood pressure
below 130 mmHg is not supported by any study. A trend
towards decrease of cerebrovascular event rate was
reported in the ONTARGET trial. This study clearly demon-
strated the equality of an ACE inhibitor and a blocker of
receptor 1 for angiotensin II. Similarly, the recommendation to lower the blood pres-
sure below 130/80 mmHg in diabetics and/or patients with
ischemic heart disease is not supported by major clinical
trials and is purely speculative. The existence of ‘‘J’’ curve was never confirmed directly.
According to some post hoc analyses performed in large
clinical trials, there probably is a certain blood pressure
threshold below which the lowering of blood pressure
would be already dangerous. One subanalysis of the trial
INVEST [12] data further divided the patients with systolic
BP below 130 mmHg into subgroups characterized by
progressive systolic BP drops of 5 mmHg and it was shown
that systolic BP o115 mmHg was associated with higher
total mortality. Epidemiologic studies also demonstrate
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70 mmHg. Intervention studies show that appropriate
target blood pressure should be 120–140/70–90 mmHg. Since clinical trials can only last a limited number of years
(for economic, medical, and social reasons), the extrapolation
of long-term prognosis of patients based on data from clinical
trials always remains speculative and has many drawbacks.
3. Hypertension, diabetes mellitus and
ischemic heart disease
Type 2 diabetes mellitus is about 20 times more common
than type 1 diabetes mellitus and the prevalence of hyperten-
sion in type 2 diabetes mellitus is as high as 70–80%. The
coexistence of hypertension and diabetes increases the risk
of both cardiovascular and renal complications, a very sensi-
tive marker of the initial insults thus being microalbumi-
nuria. It is also beyond any doubt that lowering of blood
pressure in hypertonic–diabetic patients has led to decrease
in the rate of cardiovascular complications in virtually all
studies including all types of antihypertensive medications,
i.e., diuretics, beta blockers, calcium channel blockers, ACE
inhibitors, and sartans, which means that it is the lowering of
blood pressure per se that matters. Some meta-analyses then
showed that diabetic patients profit from the treatment of
hypertension even more than non-diabetic patients do. The
2007 ESC/EHS guidelines could be interpreted such that
therapy should be started even in cases of high-normal
pressure and that the target pressure is below 130/80 mmHg.
The medications of choice should be ACE inhibitors or
sartans (ARB) in patients suffering from cough [6].
When treating hypertension in diabetics, one should bear
in mind the following: Pharmacologic antihypertensive therapy is appropriate in
patients with high-normal pressure and microalbuminuria.Fig. 1 – Blood pressure control in diabeticAll antihypertensives can be viewed as plausible options
but beta blockers and diuretics are not the first-choice
medications since they increase the insulin resistance. Non-pharmacologic measures are suitable especially in
cases of type 2 diabetes mellitus—weight loss and
decrease of sodium intake to be attempted in the first
place. Target blood pressure values are r130/80 mmHg.
 RAAS system blockade (using ACEI or ARB) is preferred.
Combination therapy is often necessary. Microalbuminuria
represents an indication for therapy with RAAS blockers
(especially those with dual excretion—trandolapril, spirapril,
fosinopril) independently of the blood pressure values. In
diabetics, we try to intervene against all risk factors because
of the high cardiovascular risk, including therapy with
statins.
4. Trials in diabetics with ischemic heart
disease and hypertension
As shown by data from the UKPDS study, patients with
hypertension, diabetes mellitus, and tight blood pressure
control have lower rate of microvascular complications. The
evaluated antihypertensives were atenolol and captopril,
tight control of hypertension being defined as blood pressure
o150/85 mmHg and less tight control as blood pressure
o180/105 mmHg. Tight blood pressure control was associated
with decrease of cerebrovascular event rate (RR 0.56; 95% CI
0.35–0.89; p¼0.013), heart failure rate (RR 0.44; 95% CI
0.20–0.94; p¼0.0043) and the risk of microvascular complica-
tions (RR 0.63; 95% CI 0.44–0.89; p¼0.0092). The more inten-
sive therapy of hypertension, however, did not have any
significant influence on the myocardial infarction rate or on
the overall mortality [13].
The ACCORD trial—blood pressure arm evaluated whether
lowering of systolic blood pressure below 120 mmHg wouldparticipants of the INVEST trial.
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ering of blood pressure below 120 mmHg vs below 140 mmHg
was not associated with any significant improvement of
cardiovascular event rate. On the contrary, the rate of side
effects was higher with more intensive hypertension treat-
ment. It has to be admitted, though, that more intensive
antihypertensive treatment was associated with decrease in
the risk of cerebrovascular events [14].
In the INVEST trial, 6400 diabetics with ischemic heart
disease and hypertension were randomized to receive ateno-
lol or verapamil combined with a diuretic or trandolapril, the
target blood pressure beingo130/85 mmHg [7]. The patients
were divided according to the achieved systolic blood pres-
sure to three groups—tight blood pressure control (o130
mmHg), usual blood pressure control (Z130–140 mmHg),
and uncontrolled blood pressure (Z140 mmHg). The highest
rate of cardiovascular events was observed in the group of
patients with uncontrolled systolic blood pressure. Surpris-
ingly, the patients with usual blood pressure control
(Z130–140 mmHg) had better prognosis than patients with
tight hypertension control and with systolic blood pressure
o130 mmHg, starting approximately from the third year of
the trial duration [12] (see Fig. 1).5. Ischemic heart disease and heart rate (HR)
Heart rate is a predictor of mortality in healthy people, in
patients with a history of hypertension, myocardial infarc-
tion, heart failure, metabolic syndrome, and in the elderly.
Resting tachycardia is associated with decreased life expec-
tancy. It is not quite clear whether this is solely the result of
sympathetic nervous system activation or whether different
pathophysiological mechanisms are involved. It thus seems
prudent to decrease the heart rate and, at the same time,
myocardial demand of oxygen. However, increased resting
heart rate has not been considered a significant risk factor for
cardiovascular disease development so far. The reason is that
no prospective trial has proved the association between heart
rate lowering and decrease of cardiovascular and overall
mortality. Similarly, it is not quite clear which heart rate is
optimal or physiological in a man. In nonhuman animals,
there is a linear association between the heart rate and
lifespan. Man is exceptional in the sense that he lives much
longer than would correspond to his heart rate. Women also
have higher heart rate than men and yet they live longer.
As early as in 1945, Levy has shown that heart rate is a risk
factor for hypertension and in 1957, Widimsky´ added that
patients with mild hypertension almost always have
increased heart frequency. In the GISSI 3 trial, heart rate over
100 bpm in patients with a history of myocardial infarction
was associated with almost 10fold increase of mortality
compared with heart rate below 60 bpm [15]. Based on data
from clinical trials, the risk factor is now defined as heart
frequency Z70 bpm.
By lowering the heart rate we attempt to control both
mortality and complications, including heart failure. It can-
not be excluded so far that the positive influence of
bradycardia-inducing medications is related rather to their
other pharmacological qualities while the heart rate loweringrepresents just a side effect. Cardiologic medications used
with the specific aim to control the heart rate include
verapamil-type calcium channel blockers (phenylalkyla-
mines), beta blockers (without ISA activity), digitalis, and If
channel blockers.
In the Danish DAVIT II trial, 878 patients with a history of
myocardial infarction received verapamil 360 mg daily and
897 patients with the same history were given placebo.
Treatment was initiated between 7 and 14 days after the
myocardial infarction and lasted for 18 months while all
patients taking beta blockers were excluded. After 1.5 years of
treatment, a trend in favor of verapamil was observed, the
risk of major cardiovascular events being 20% lower (p¼0.03)
[16]. In the international INVEST trial comprising 22,576
patients with a history of myocardial infarction, verapamil-
based treatment was associated with the same risk of death,
re-infarction or cerebrovascular event as atenolol-based
treatment, atenolol being considered the gold standard until
then. Significantly less newly diagnosed diabetics were iden-
tified, however, in the group with verapamil-based treatment
and these diabetics had significantly less cardiovascular
events [10]. Good blood pressure control o140/90 mmHg
during the entire trial was associated with the lowest cardi-
ovascular event rate. Patients with blood pressure below 140/
90 mmHg during more than 3/4 visits suffered from cardio-
vascular events half less often than patients with good blood
pressure control during every 4th visit only. Systolic blood
pressure o115 mmHg was associated with highly significant
increase in mortality [12].
Lowering of heart rate in cases of heart failure should result
in left ventricular function improvement, slowing of the
progression of heart failure and eventually in decrease of
the cardiovascular event rate including cardiovascular
mortality—i.e., in improving the prognosis. Large clinical
trials with beta blockers showed that significant improve-
ment of prognosis does indeed occur in patients with chronic
heart failure. In the CIBIS trial, for example, treatment with
bisoprolol lead to decrease of resting heart rate by about
15 bpm compared to placebo [17]. Heart rate lowering repre-
sented the most robust predictor of survival in a multivariate
analysis of data acquired in this trial. The ensuing and larger
CIBIS II trial demonstrated that resting heart rate and the
change in heart rate during treatment were significant pre-
dictors of mortality [18]. The best prognosis was associated
with the lowest basal resting heart rate and with the highest
drop in heart rate during therapy.
The role of digoxin in patients with IHD was studied in
most detail by the DIG trial. The total number of 6,800
patients was randomized to digoxin or placebo with the
possibility to add-on either ACE inhibitor or diuretic. The
overall mortality remained unchanged. The only two out-
comes influenced positively and significantly by digoxin were
the total number of hospitalizations and the number of
hospitalizations for heart failure [19].
BEAUTIFUL was a clinical trial focusing on the question
whether a decrease in the heart rate caused by a specific
inhibitor of If channels in the sinoatrial node – ivabradine –
would result in lowering of the cardiovascular mortality and
morbidity in patients with stabilized ischemic heart disease
and systolic dysfunction of the left ventricle [20,21]. In the
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heart rate represents a marker of future cardiovascular
mortality and morbidity. Total number of 10,917 patients
with documented IHD and left ventricular ejection frac-
tiono0.40 was enrolled and these patients were randomized
to ivabradine or placebo. In the entire study population,
ivabradine did not show any benefit with respect to both
primary and secondary endpoint compared to placebo. Sub-
analyses within the placebo group compared patients with
resting heart rate Z70 bpm vso70 bpm and revealed that
patients with heart rate Z70 bpm had a higher risk of
cardiovascular mortality (by 34%; p¼0.0041), hospitalizations
for heart failure (by 53%; po0.001), hospitalizations for
myocardial infarction (by 46%; p¼0.0066), and coronary
revascularization (by 38%; p¼0.037). Treatment with ivabra-
dine was safe and well tolerated.
SHIFT was a following trial aimed at testing the hypothesis
that lowering of heart rate per se by ivabradine in patients with
chronic heart failure would decrease cardiovascular event rate
[22]. Total number of 6,558 patients with systolic heart failure of
ischemic or non-ischemic etiology, NYHA class II–IV, ejection
fraction r0.35, and sinus rhythm of Z70 bpm at the baseline
was enrolled. Enrolled patients were treated according to
current recommendations for the treatment of heart failure
including beta blockers. After mean follow-up period of 23
months, ivabradine treatment resulted in a mean heart rate
drop of 8 bpm compared to placebo. This heart rate lowering
resulted in decrease of the composite primary clinical endpoint
(cardiovascular mortality and hospitalizations for progression of
heart failure) by 18% (po0.0001). This decrease could be primar-
ily explained by drop in hospitalizations for heart failure by 26%
(po0.0001) and deaths caused by heart failure by 26% (p¼0.014).
Lowering of cardiovascular mortality per se with ivabradine by
9% failed to reach statistical significance (p¼0.128).
Bradycardia-inducing medications have a clear role in the
treatment of patients with a history of myocardial infarction
and they have other pharmacological properties besides
lowering of heart rate – they increase the myocardial con-
tractility, decrease the sympathetic activity and cause vaso-
dilatation. Thus, their use has clear indications but also
contraindications. Digitalis is indicated in cases of atrial
fibrillation; beta blockers should be given to most patients
with dominant heart failure; verapamil SR is beneficial in
patients without heart failure and with a heart rate470 bpm,
atrial fibrillation, diabetes or metabolic syndrome, and in all
cases where beta blockers are contraindicated. Ivabradine
treatment is most appropriate in patients with heart failure
and heart rate470 bpm together with a maximal tolerated
beta blocker dosage.6. Conclusion
The treatment of hypertension in patients with a history of
myocardial infarction is based on the following: Blockade of the renin – angiotensin – aldosterone system.
Angiotensin-converting enzyme inhibitors (ACE-I), block-
ers of receptor 1 for angiotensin II (ARB) and aldosterone
blockers (in patients with heart failure) are used. Beta blockers—selective beta blockers without ISA should
be preferred. If not tolerated, verapamil can be used in
patients without heart failure. In patients with atrial fibrillation, beta blockers are recom-
mended; verapamil and digitalis offer the control of both
rhythm and frequency; ACE inhibitors or ARB represent a
so called upstream therapy. Target blood pressure iso140/90 mmHg.
 Target heart rate isr70 bpm (EBM for patients with heart
failure). Ivabradine is recommended in patients with heart rate470
bmp together with a maximal tolerated beta blocker dosage. Hypolipidemics should also be given—mostly statins, with
a target total cholesterol level below 200 mg/dl (4.5 mmol/l).
If triglycerides are high, HDL cholesterol is low, and the
patient is on antiplatelet therapy, fibrates can be added. The
cornerstone of antiplatelet therapy is an acetylsalicylic acid
in doses 75–360 mg, combined with clopidogrel for several
months. Alternative use of prasugrel a ticagrelor is already
suggested by the new recommendations.Acknowledgements
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